These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 30411235)

  • 21. The list of prohibited substances and methods in sport: structure and review process by the world anti-doping agency.
    Mazzoni I; Barroso O; Rabin O
    J Anal Toxicol; 2011 Nov; 35(9):608-12. PubMed ID: 22080899
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Annual banned-substance review: the Prohibited List 2008-analytical approaches in human sports drug testing.
    Thevis M; Kuuranne T; Geyer H; Schänzer W
    Drug Test Anal; 2009 Jan; 1(1):4-13. PubMed ID: 20355153
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Analytical challenges in the detection of peptide hormones for anti-doping purposes.
    Barroso O; Handelsman DJ; Strasburger C; Thevis M
    Bioanalysis; 2012 Jul; 4(13):1577-90. PubMed ID: 22831474
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacology of stimulants prohibited by the World Anti-Doping Agency (WADA).
    Docherty JR
    Br J Pharmacol; 2008 Jun; 154(3):606-22. PubMed ID: 18500382
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An Abductive Inference Approach to Assess the Performance-Enhancing Effects of Drugs Included on the World Anti-Doping Agency Prohibited List.
    Breenfeldt Andersen A; Jacobson GA; Bejder J; Premilovac D; Richards SM; Rasmussen JJ; Jessen S; Hostrup M
    Sports Med; 2021 Jul; 51(7):1353-1376. PubMed ID: 33811295
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Performance-enhancing drugs: understanding the risks.
    Hatton CK; Green GA; Ambrose PJ
    Phys Med Rehabil Clin N Am; 2014 Nov; 25(4):897-913. PubMed ID: 25442165
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ecdysteroids as non-conventional anabolic agent: performance enhancement by ecdysterone supplementation in humans.
    Isenmann E; Ambrosio G; Joseph JF; Mazzarino M; de la Torre X; Zimmer P; Kazlauskas R; Goebel C; Botrè F; Diel P; Parr MK
    Arch Toxicol; 2019 Jul; 93(7):1807-1816. PubMed ID: 31123801
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ergogenic effects of inhaled beta2-agonists in non-asthmatic athletes.
    Wolfarth B; Wuestenfeld JC; Kindermann W
    Endocrinol Metab Clin North Am; 2010 Mar; 39(1):75-87, ix. PubMed ID: 20122451
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Athlete Biological Passport: an integral element of innovative strategies in antidoping.
    Vernec AR
    Br J Sports Med; 2014 May; 48(10):817-9. PubMed ID: 24659508
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treating the elite athlete: anti-doping information for the health professional.
    Tandon S; Bowers LD; Fedoruk MN
    Mo Med; 2015; 112(2):122-8. PubMed ID: 25958657
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Introduction to the application of capillary gas chromatography of performance-enhancing drugs in doping control.
    Müller RK; Grosse J; Thieme D; Lang R; Teske J; Trauer H
    J Chromatogr A; 1999 May; 843(1-2):275-85. PubMed ID: 10399856
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Annual banned-substance review: Analytical approaches in human sports drug testing.
    Thevis M; Kuuranne T; Geyer H
    Drug Test Anal; 2019 Jan; 11(1):8-26. PubMed ID: 30488582
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Can β2-agonists have an ergogenic effect on strength, sprint or power performance? Systematic review and meta-analysis of RCTs.
    Riiser A; Stensrud T; Stang J; Andersen LB
    Br J Sports Med; 2020 Nov; 54(22):1351-1359. PubMed ID: 32747344
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nutritional supplements and ergogenic AIDS.
    Liddle DG; Connor DJ
    Prim Care; 2013 Jun; 40(2):487-505. PubMed ID: 23668655
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Annual banned-substance review: analytical approaches in human sports drug testing.
    Thevis M; Kuuranne T; Geyer H; Schänzer W
    Drug Test Anal; 2010 Apr; 2(4):149-61. PubMed ID: 20376830
    [TBL] [Abstract][Full Text] [Related]  

  • 36. β
    Hudzik TJ; Patel M; Brown A
    Drug Test Anal; 2021 Feb; 13(2):261-267. PubMed ID: 33369180
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pheromones: a new ergogenic aid in sport?
    Papaloucas M; Kyriazi K; Kouloulias V
    Int J Sports Physiol Perform; 2015 Oct; 10(7):939-40. PubMed ID: 25710097
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Recreational and ergogenic substance use and substance use disorders in elite athletes: a narrative review.
    McDuff D; Stull T; Castaldelli-Maia JM; Hitchcock ME; Hainline B; Reardon CL
    Br J Sports Med; 2019 Jun; 53(12):754-760. PubMed ID: 31097457
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The ELSA trial: single versus combinatory effects of non-prohibited beta-2 agonists on skeletal muscle metabolism, cardio-pulmonary function and endurance performance-study protocol for a randomized 4-way balanced cross-over trial.
    Zügel M; Bizjak DA; Nussbaumer D; Winkert K; Takabayashi K; Kirsten J; Washington M; Treff G; Dreyhaupt J; Steeb L; Diel P; Parr MK; Steinacker JM; Persch H
    Trials; 2021 Dec; 22(1):903. PubMed ID: 34895300
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Can furosemide mask the use of performance-enhancing drugs?].
    Brinkman DJ; Tichelaar J; Van Agtmael MA
    Ned Tijdschr Geneeskd; 2021 May; 165():. PubMed ID: 34346634
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.